Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Free Report) traded down 3.7% during trading on Thursday . The stock traded as low as $1.29 and last traded at $1.30. 17,543 shares traded hands during trading, a decline of 99% from the average session volume of 1,241,034 shares. The stock had previously closed at $1.35.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Processa Pharmaceuticals in a report on Thursday, October 3rd.
View Our Latest Report on PCSA
Processa Pharmaceuticals Stock Performance
Processa Pharmaceuticals (NASDAQ:PCSA – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.03). As a group, equities analysts anticipate that Processa Pharmaceuticals, Inc. will post -3.78 earnings per share for the current year.
About Processa Pharmaceuticals
Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.
See Also
- Five stocks we like better than Processa Pharmaceuticals
- Consumer Discretionary Stocks Explained
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What to Know About Investing in Penny Stocks
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Manufacturing Stocks Investing
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Processa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Processa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.